THE MAMPROTECH STORY
We are an Australian biotechnology company based in Sydney, Australia that was established in year 2007 by a group of scientists from University of New South Wales and University of Sydney. We are currently located at the Cicada Innovation Centre, Australian Technology Park, Cornwallis St., Eveleigh, NSW 2015.
Many of our key personnel are well respected scientists in the academe and entrepreneurs in the business industry. Our company works closely with universities and industry partners in Australia and overseas to develop new technologies such as synthesis of new and rare chemicals, biomaterial technologies, and cell-based technologies. In fact, many of our technologies are not available in other parts of the world. Mamprotech technologies are applied directly to human tissue engineering and regeneration as well as treatment to some very intractable human ailments.
We understand the unique market that we operate in. Thus, it is very important for us to have a comprehensive study of the industry in order to ensure the profitability and sustainability of our company.
Fortunately, the biomaterial and medical technology industry is one of the most rapidly growing industry in the world, driven by the increasing affluence of developed and developing countries. Consequently, as life expectancy increases so are the demands for a higher quality life.
It has come to our understanding that the global technology market is valued at over AUD $440 billion a year and is one of the fastest growing markets all over the world. Currently, the major markets for medical devices are in the developed economies such as North America, Europe, the United Kingdom and Japan. However, the future promises to be quite different with Asian markets due to the fact that medical devices are growing rapidly. It has been predicted that the Asian markets will overtake those of Europe and North America in just a matter of 15 years.
With the promise of growth and sustainability that this industry awaits for us, we have decided to expand our market reach and establish a manufacturing company in Australia as well as other part of Asia to start our product distribution all over Asia. We will offer our three technologies, all of which are unique and new to the Asian market. We are confident that these products will surely attract the Asian market and generate greater demands for all of it are positioned and crafted for the emerging medical device market. Above all, our products are coupled with low labour, low manufacturing cost and strong local government support, which provides us the edge to market and sell new, top-quality products at a lower cost. Having stated our goals for Mamprotech, we have detailed below our rationale and main objectives for the company for the succeeding years:
GOAL 1: Establish manufacturing in Vietnam and start distribution in Asia
GOAL 2: Become cash flow positive for our second year of operation in Vietnam
GOAL 3: Widen marketing network to Asia, then Europe and ultimately the USA
GOAL 4: Expand manufacturing into novel pipeline technologies
GOAL 5: All R&D will be conducted in Australia and all manufacturing will be conducted in Vietnam
We understand the risks and potential threats that this venture awaits us. However, we are confident of the management team that will lead Mamprotech to success and profitability over the coming years:
DR. GIANG TRAN: Dr Tran is a medical scientist who has extensive experience in biotechnology and unique expertise in Australia in the area of tissue implants, heart valves and tissue patches.
PROF. ANDREW RUYS: He has more than 25 years of experience in biomedical engineering research and commercialisation and also a key participant in the successful founding of two companies in Australia.
MR. DUC QUANG NGUYEN: He has more than 22 years of senior management experience with proven record in managing many major companies in Vietnam such as Spotlight Co., Quang Phuoc Co., Hoa Lam Kymco Corp, Saigon Hi-Tec Healthcare Park, and Vietbank. He was a member of the Board of Directors in all these companies
Having been operating in the market for more than a decade, our financial goals for Mamprotech never changes---that is to continually gain increasing profitability and sales for the coming years. Thus, our financial goals for the next three years are as follows:
✓ To achieve a net profit margin of over 15% by 2020 ✓ To maintain the net profit growth by year 2021 and achieve a net profit of at least $2 million by 2021
Through the assistance and collaboration of our excellent management team and integration of Mamprotech’s one-of-a-kind technologies, we expect that the company will aggressively expand over the coming years of operation as shown in the following chart which indicates the projected sales, gross margin and net profit for year 2019 to 2021: